Advancing knowledge in chronic liver disease through evidence-based research.
AbstractsPublication policy

Showing 2 of 2 papers

The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis

Reiberger T, Berzigotti A, Trebicka J, Ertle J, Gashaw I, Swallow R, Tomisser A.

Trials 2023, 24(1): 293

DOI: 10.1186/s13063-023-07291-3

Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: Study protocol for a randomized controlled trial

Madsen BS, Trebicka J, Thiele M, Israelsen M, Arumugan M, Havelund T, Krag A.

Trials 2018, 19(1): 143

DOI: 10.1186/s13063-018-2523-9